stockrow
Saturday 7 November 2026
Export PGEN’s income statement to Excel — free account
Precigen, Inc.
PGEN Healthcare Biotechnology
Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024.
- Revenue
- +2,437.6%
- EPS
- +109.4%
- Free cash flow
- +140.3%
- Total debt
- +1.47%
Quarter to September 2026, against a year earlier
4.43
0.21
+4.98%
Follow PGEN
Alert me
Precigen, Inc. (PGEN) P/E ratio
As of 6 November 2026, Precigen, Inc. (PGEN) trades at a P/E ratio of 60.3×. Over the past ten years it has ranged from 0.0× (September 2026) to 116× (September 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 10.6× and above the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 10.5× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 116× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 116×
Ten-year median
0.0×
Current reading's percentile
99
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IMCR Immunocore Holdings PLC Sponsored ADR compare | n/m |
| NUVB Nuvation Bio Inc. compare | n/m |
| QURE uniQure N.V. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | n/m |
| PGEN Precigen, Inc. | 60.3× |
| BRVE Braveheart Bio, Inc. compare | — |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)